Pentraxin-3 in Thrombolytic Therapy for Acute Ischemic Stroke: No Relation with Curative Effect and Prognosis

Abstract

BackgroundPentraxin-3 (PTX3) is considered a high quality inflammatory marker of the severity and prognosis of several diseases, however, the value of PTX3 in thrombolytic therapy for acute ischemic stroke remains unclear and PTX3 is still controversial in evaluating the prognosis of stroke patients. In this study, we investigated the association of PTX3 with thrombolytic therapy in patients with acute ischemic stroke.Material/MethodsForty-seven stroke patients who received thrombolytic therapy within 4.5 hours after symptom onset were enrolled consecutively between July 2016 and June 2017. All the patients underwent multiphase CTA (computerized tomography angiography) or CT perfusion before thrombolysis with no indication for endovascular treatment. Initial and 24 hours of National Institute of Health Stroke Scale (NIHSS) scores and serum PTX3 level, stroke risk factors and predictors, and mRS (modified Rankin scale) at 3 months were collected prospectively. Predictors of thrombolytic therapy effect and long-term prognosis were investigated by univariate and multivariate logistic regression.ResultsThe 24 hour NIHSS score and the treatment time was associated with symptom improvement, while the PTX3 level had no association with neurological improvement and prognosis in stroke patients receiving thrombolytic therapy.ConclusionsPTX3 is not suitable to serve as an indicator of thrombolytic efficacy and had no association with long-term prognosis in stroke patients receiving thrombolytic therapy.

Fatores De Risco Associados Ao Déficit Neurológico Em Pessoas Vítimas De Acidente Vascular Cerebral Isquêmico

“…(6,17) A pontuação NIHSS de 24 horas e o tempo de tratamento estão associados à melhora da condição neurológica. (19) Os resultados obtidos no presente estudo, em relação ao tempo da janela de tratamento, demonstram um bom tempo médio alcançado, visto que a média obtida se encontra abaixo dos 270 min preconizado como tempo máximo na realização da trombólise endovenosa. (6) Estudo (11) demonstrou um tempo médio de 191 minutos, resultado semelhante ao encontrado em pesquisa semelhante (14) que obteve tempo médio de janela terapêutica de 194,4±42 minutos.…”

Serum pentraxin 3 as a biomarker for prognosis of acute minor stroke due to large artery atherosclerosis

“…PTX3 may also be an active mediator of endothelial dysfunction and atherosclerotic plaque vulnerability (Ryu et al., 2012; Sezer et al., 2014). In one study directed at identifying a role for PTX3 in thrombolytic therapy in acute ischemic stroke, no association between PTX3 and neurological improvement and long‐term prognosis were observed (Zhang et al., 2018). Therefore, substantial evidence exists suggesting a dual role for PTX3 as a modulator or amplifier of the innate immune response.…”